Maruishi Pharmaceutical Co. Ltd.

What Maruishi Pharmaceutical Co. Ltd. does

Maruishi Pharmaceutical Co., Ltd. is a privately held Japanese specialty pharmaceutical company headquartered in Osaka. Founded in 1888 as a manufacturer of Japanese Pharmacopoeia essential drugs and incorporated as a stock company in 1936, the company focuses on two therapeutic domains: perioperative medicine and infection control. Its perioperative portfolio includes SEVOFRANE (sevoflurane), an inhalation general anesthetic marketed in over 100 countries following its 1995 FDA approval; PRECEDEX (dexmedetomidine), an alpha-2 adrenergic agonist sedative launched in 2004; and POPSCAINE, a long-acting local anesthetic launched in 2008. The infection control portfolio comprises alcohol-based hand antiseptics including WELPAS (pioneered in 1985 as Japan's first alcohol lotion-based hand antiseptic), WELCEPT, WELFOAM, and STERIHYDE (a glutaral-based disinfectant launched in 1978). Maruishi also maintains stable supply of basic drugs listed in the Japanese Pharmacopoeia, which it has manufactured since its founding.

The company operates an integrated manufacturing and R&D infrastructure: the Imazu Plant in Osaka produces approximately 30 products across sterile and general preparation zones, while the Central Research Laboratories (established 1983, with a 1993 annex) conduct R&D in perioperative, infection control, and cancer supportive care. Maruishi holds GMP, GDP, GCP, and GLP compliance certifications and operates FDA-approved manufacturing. Headcount stood at 491 employees as of March 31, 2026.

Maruishi generates revenue primarily through prescription pharmaceutical sales to medical institutions in Japan via pharmaceutical wholesalers, with international revenue flowing through channel partners in each country or region. The go-to-market model is sales-led, with Medical Representatives providing evidence-based information to healthcare professionals in surgery, anesthesiology, and infection prevention. For FY2025 (April 2025 to March 2026), the company reported revenue of ¥48.3 billion (approximately $320M USD) and current profits of ¥4 billion. Revenue rose from ¥35.2 billion in FY2021 to ¥48.3 billion in FY2025, an approximately 8.2% CAGR. Leadership rests with the Inoue family, and the company has no public listing, venture capital, or private equity backing disclosed.

Name

Maruishi Pharmaceutical Co. Ltd.

Legal name

丸石製薬株式会社

Website

https://maruishi-pharm.co.jp

Company type

Private

Founded year

1888

Operating status

Operating

Headcount range

1–10 employees

Short description

Maruishi Pharmaceutical is a privately held Japanese specialty pharma, founded 1888 and headquartered in Osaka, focused on perioperative medicines (anesthetics, sedatives, analgesics) and infection control disinfectants. It sells via wholesalers to medical institutions in Japan and licenses SEVOFRANE to over 100 countries.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Pain Management & Anesthesiology Pharmaceuticals (HLAIAAAN), Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)

Keywords

• Perioperative pharmaceuticals
• Anesthetic manufacturing
• Infection control products
• Antiseptic solutions
• Japanese Pharmacopoeia drugs

Headquarters

HQ city

Osaka

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Manufacture and sales of medical drugs including anesthetics, analgesics, sedatives, disinfectants, and Japanese Pharmacopoeia drugs. Revenue from product sales to healthcare institutions and through pharmaceutical distributors.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Maruishi Pharmaceutical is a specialty pharmaceutical manufacturer that develops, produces, and sells prescription drugs focused on the perioperative (pre-, intra-, and post-surgical) area and infection control. Its portfolio spans inhalation anesthetics, sedatives, long-acting local anesthetics, alcohol-based hand antiseptics, glutaral disinfectants, and Japanese Pharmacopoeia basic drugs, manufactured at its Imazu Plant in Osaka and distributed through pharmaceutical wholesalers to medical institutions.

Product overview

Maruishi Pharmaceutical Co. Ltd. is a Specialty Pharma company focused on the perioperative and infection control areas. The company offers a portfolio of pharmaceutical products centered around three main pillars: (1) Anesthetics and sedatives including SEVOFRANE® (general anesthetic), PRECEDEX® (sedative), and POPSCAINE® (local anesthetic); (2) Disinfectants/antiseptics including WELPAS®, WELCEPT®, WELFOAM® (alcohol-based hand rubs), and STERIHYDE® (glutaral preparation); and (3) Basic Drugs (Japanese Pharmacopoeia drugs). The company operates as a research-driven pharmaceutical manufacturer providing full line-up products in perioperative and infection control fields, with approximately 30 product items manufactured at the Imazu Plant.

Differentiator

Problem solved

Functional benefit

Products and services

• SEVOFRANE® (Sevoflurane) General inhalation anesthetic used during surgery; the company's flagship perioperative product, approved by FDA in 1995 and marketed in over 100 countries worldwide.
• PRECEDEX® (Dexmedetomidine) Alpha-2 adrenergic agonist sedative used for sedation during medical procedures and in ICU settings.
• POPSCAINE® (Long-acting local anesthetic) Long-acting local anesthetic used for pain management and postoperative analgesia.
• WELPAS® Antiseptic Solution Alcohol-based hand rub disinfectant pioneered as the first alcohol lotion-based hand antiseptic in Japan, widely used in medical institutions for hand hygiene.
• WELCEPT® (Alcohol-based hand rub) Alcohol-based hand rub disinfectant used for hand hygiene in medical settings.
• WELFOAM® (Foaming alcohol-based hand rub) Foaming alcohol-based hand rub disinfectant for hand hygiene in medical and clinical settings.
• STERIHYDE® (Glutaral disinfectant)

Quantifiable outcome

• SEVOFRANE marketed in over 100 countries worldwide
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Shizuoka UniversityminorStrategic or Co-development Partner · 26 February 2026Joint development of educational materials combining disaster prevention and infection control measures for high school students.
• FRONTEOcoreStrategic or Co-development Partner · 16 February 2026Strategic business partnership for drug discovery R&D. Maruishi Pharmaceutical and FRONTEO signed a strategic business partnership agreement for drug discovery research and development. Announced February 16, 2026.
• Cara TherapeuticsminorStrategic or Co-development PartnerOriginator for difelikefalin acetate (MR13A9/a) - drug candidate for postoperative pain. Development in Phase II in Japan, Phase III overseas.
• EVA TherapeuticsminorStrategic or Co-development PartnerCo-development partner for perfluorodecalin (EVA101) - medical device for improving oxygenation in hypoxemia patients. Phase I development in Japan.
• Allay TherapeuticsminorStrategic or Co-development PartnerPartner for bupivacaine hydrochloride hydrate (ATX101) - sustained-release implant for pain management after total knee arthroplasty. Phase I/II in Japan, Phase II overseas.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Baxter International: Large global specialty pharma with a leading inhalation anesthetic and perioperative franchise, including its own sevoflurane offering. Directly competes with Maruishi/SEVOFRANE in operating rooms and anesthesia delivery worldwide, with comparable patient and provider customer base.
• Mochida Pharmaceutical: Japan-headquartered specialty pharma of similar size (~$300M USD revenue range) focused on women’s health, circulatory, and specialty therapeutic areas. Closely comparable as a mid-sized privately-positioned Japanese specialty pharma competing for the same Japanese medical-institution channel.
• Nippon Chemiphar: Japan-based specialty pharma focused on generic and specialty finished dosage forms in therapeutic areas including anesthesia and pain. Direct comparable in scale and channel as a Japanese specialty pharma selling into the same hospital/MR channels.
• Teva Pharmaceutical Industries: Global specialty/generic pharma with a significant injectable anesthesia and perioperative offering, including generic sevoflurane and other anesthetics. Closely comparable as a competitor selling into the same perioperative formulary position on a global basis.

Broad incumbents

• AbbVie: Major pharma incumbent that inherited and markets the SEVOFRANE franchise in the U.S. (via the legacy Abbott anesthesia business) and has a broader sedative/analgesic portfolio overlapping with Maruishi's perioperative positioning.
• Eisai Co., Ltd. Japanese specialty pharma major with a franchise approach across neurology, oncology, and specialty care. Larger than Maruishi but highly comparable as a Japan-headquartered specialty pharma selling branded Rx through medical representatives to hospitals.
• Pfizer (Hospital / Injectables business, ex-Hospira): Through the legacy Hospira franchise, Pfizer is a major global supplier of injectable anesthetics, sedatives, and analgesics used in perioperative care. Overlaps with Maruishi across injectable sedation and pain management sold to the same hospital buyers.

Emerging players

• Piramal Pharma Solutions: India-based specialty pharma with an inhalation anesthetic and injectable anesthesia business built through acquisitions. Comparable as a non-Japanese specialty anesthesia player targeting overlapping perioperative customers in emerging and developed markets.

Regional players

• Aspen Pharmacare: South Africa-headquartered specialty pharma with a focused anesthesia, thrombosis, and specialty branded portfolio distributed primarily in emerging markets and select international regions. Comparable model as a non-Big-Pharma specialty player expanding anesthesia products internationally.

Others

• STERIS: Global leader in infection prevention, sterilization, and surgical/operating-room consumables serving the same hospitals as Maruishi. Adjacent rather than directly competitive, but serves the same infection-control buyer and overlaps on the hospital hygiene/disinfection value proposition behind WELPAS/WELCEPT/WELFOAM/STERIHYDE.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xtwitter.com/maruishiseiyaku
• LinkedInlinkedin.com/company/maruishi-pharmaceutical-co-ltd-

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maruishi Pharmaceutical Co. Ltd.